First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Clinically Important Outcomes of Interest in the Comparative Effectiveness Review (2 of 3)
For assessing schizophrenia, positive symptoms were often evaluated with the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Positive Symptoms (SAPS). Negative symptoms were often evaluated with the PANSS and the Scale for the Assessment of Negative Symptoms (SANS). General psychopathology was assessed with the Agitated Behavior Scale (ABS), the Agitation-Calmness Evaluation Scale (ACES), the Calgary Depression Scale for Schizophrenia (CDS-S), the Hamilton Anxiety Scale (HAM-A), the Hamilton Depression Scale (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), and the PANSS. Global ratings and total scores were reported using the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impressions–Improvement Subscale (CGI-I), the CGI–Severity Subscale (CGI-S), and the PANSS.
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.